GlassScriptPhysician profile
Gregory G Allen
NPI 1043217250
$37,925.68
in general payments reported to CMS, 2019-2025
37 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,567 · 2020: $15K · 2021: $9,767 · 2022: $5,311 · 2023: $651 · 2024: $929 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Consulting Fee: $1,065 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.93 |
| Consulting Fee | $1,065.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,277.28 | 2021-2025 | Qulipta, Ubrelvy, Synthroid |
| Allergan, INC. | $15,170.52 | 2019-2021 | |
| Pfizer INC. | $2,110.46 | 2019-2025 | |
| Novo Nordisk INC | $1,332.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.79 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Amgen INC. | $528.53 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $354.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $348.05 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $328.50 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $286.70 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $265.82 | 2019-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $204.51 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $136.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $128.39 | 2019-2020 | |
| Inspire Medical Systems, INC. | $115.67 | 2024-2025 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $112.52 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $66.92 | 2025 | Gemtesa |
| Verona Pharma, INC. | $60.68 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $55.06 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $41.73 | 2024 | Voquezna |
| Boston Scientific Corporation | $36.51 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.67 | 2020 | |
| Ironwood Pharmaceuticals, INC | $30.57 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $30.56 | 2019 | |
| Biogen, INC. | $23.99 | 2025 | Skyclarys |
| Lundbeck LLC | $23.64 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $22.62 | 2025 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $18.36 | 2024 | Gvoke Hypopen |
| Eisai INC. | $17.66 | 2020 | |
| Sanofi Pasteur INC. | $17.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.79 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.